VIP peptide research: what the human trials show
VIP, or vasoactive intestinal peptide, is a 28-amino-acid neuropeptide whose synthetic form, aviptadil, has been tested in randomized human trials. Here is what those trials found.
Findings
- In a 196-patient randomized trial in COVID-19 respiratory failure, survival at 60 days was twice as likely on aviptadil (odds ratio 2.0, 95% confidence interval 1.1 to 3.9, p=0.035).
- Among patients already on mechanical ventilation, the odds of survival were ten-fold higher than placebo (p=0.031).
- Interleukin-6, a central inflammatory signal, was significantly reduced by day three (p=0.02), alongside improvement in the respiratory distress ratio.
- In sarcoidosis, four weeks of inhaled VIP significantly reduced tumour necrosis factor alpha production by lung cells and raised regulatory T cells, the first demonstration of an immunoregulatory effect of VIP in humans.
- A single inhaled dose in pulmonary hypertension produced selective pulmonary vasodilation and improved stroke volume, with no side effects reported.
Respiratory failure: a 60-day survival difference (Crit Care Med, 2022)
A multicentre, placebo-controlled trial across ten United States hospitals randomized 196 patients with COVID-19 respiratory failure two-to-one to three days of intravenous aviptadil or placebo. The odds of surviving to 60 days were twice as high on aviptadil (odds ratio 2.0, 95% confidence interval 1.1 to 3.9, p=0.035). The respiratory distress ratio improved and interleukin-6 release fell significantly by day three (p=0.02). Among patients on mechanical ventilation at baseline, the odds of survival were ten-fold higher than placebo (p=0.031), and those on high-flow nasal oxygen were significantly more likely to reach the combined endpoint (p=0.039). The combined primary endpoint of being alive and free from respiratory failure at day 60 did not reach significance on its own, and a later multicentre trial did not confirm the survival result. No drug-related serious adverse events were reported.
Sarcoidosis: inflammatory signalling in the lung (Am J Respir Crit Care Med, 2010)
Twenty patients with biopsy-confirmed sarcoidosis and active disease inhaled nebulised VIP for four weeks in an open phase II study. Inhalation was safe and well tolerated. Cells taken from the patients’ lungs produced significantly less tumour necrosis factor alpha, the cytokine central to granuloma formation in this disease, and the number of regulatory T cells in the lung rose. Laboratory work in the same paper showed VIP converting naive T cells into regulatory T cells. The authors described it as the first study to show an immunoregulatory effect of VIP in humans.
Pulmonary hypertension: blood flow measured directly (Eur Respir J, 2008)
Twenty patients with pulmonary hypertension inhaled a single 100-microgram dose of aviptadil while their heart pressures were being measured directly by right-heart catheterisation. The inhaled peptide produced a small, temporary but significant selective widening of the lung blood vessels, improved stroke volume and raised mixed venous oxygen saturation. Six of the twenty had a fall in pulmonary vascular resistance of more than 20 per cent. The effect was short-lived, it caused no side effects, and in patients with significant lung disease oxygenation tended to improve.
What VIP is
VIP is a 28-amino-acid neuropeptide found throughout the body and present in high concentration in the lungs, where much of the human research has been done. It acts at the VPAC receptors, and research interest centres on two effects seen repeatedly above: damping of inflammatory signalling, and relaxation of blood vessel walls. The synthetic form used in trials is called aviptadil.
Vistara Labs stocks VIP research vials and a ready-mixed VIP nasal spray, shipped from within Canada to every province.
Frequently asked questions
Has VIP been tested in humans?
Yes. Synthetic VIP, called aviptadil, has been given in randomized human trials. The largest randomized 196 patients with COVID-19 respiratory failure, and smaller studies used inhaled VIP in sarcoidosis and in pulmonary hypertension.
What did the largest VIP trial measure?
It measured survival and freedom from respiratory failure at 60 days in 196 patients. Survival at 60 days was twice as likely on aviptadil (odds ratio 2.0, 95% confidence interval 1.1 to 3.9, p=0.035), and interleukin-6, a marker of inflammation, fell by day three (p=0.02).
What is VIP?
VIP, or vasoactive intestinal peptide, is a 28-amino-acid neuropeptide found throughout the body and concentrated in the lungs. Research interest centres on its effect on inflammatory signalling and on blood vessel tone.
Sources: Youssef JG, et al. The use of IV vasoactive intestinal peptide (aviptadil) in patients with critical COVID-19 respiratory failure: results of a 60-day randomized controlled trial. Crit Care Med. 2022;50:1545-54. PMID 36044317. Prasse A, et al. Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. Am J Respir Crit Care Med. 2010;182:540-8. PMID 20442436. Leuchte HH, et al. Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J. 2008;32:1289-94. PMID 18978135. Brown SM, et al. Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO). Lancet Respir Med. 2023;11:791-803. PMID 37348524.
All products supplied by Vistara Labs are intended for laboratory research use only. They are not drugs, are not approved for human or veterinary use, and are not intended to diagnose, treat, cure or prevent any condition. Nothing on this page constitutes medical advice or guidance for use in humans.